Header Logo

Connection

John Zajecka to Secondary Prevention

This is a "connection" page, showing publications John Zajecka has written about Secondary Prevention.
Connection Strength

0.865
  1. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry. 2020 03 01; 77(3):237-245.
    View in: PubMed
    Score: 0.170
  2. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019 09 01; 76(9):893-903.
    View in: PubMed
    Score: 0.164
  3. Residual symptoms in major depressive disorder: prevalence, effects, and management. J Clin Psychiatry. 2013 Apr; 74(4):407-14.
    View in: PubMed
    Score: 0.105
  4. Residual symptoms and relapse: mood, cognitive symptoms, and sleep disturbances. J Clin Psychiatry. 2013; 74 Suppl 2:9-13.
    View in: PubMed
    Score: 0.103
  5. SNRIs in the management of acute major depressive disorder. J Clin Psychiatry. 2004; 65 Suppl 17:11-8.
    View in: PubMed
    Score: 0.055
  6. Antidepressant dosing and switching guidelines: focus on nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:42-7.
    View in: PubMed
    Score: 0.048
  7. Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry. 2001; 62 Suppl 3:35-43.
    View in: PubMed
    Score: 0.045
  8. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry. 1999 Jun; 60(6):389-94.
    View in: PubMed
    Score: 0.040
  9. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
    View in: PubMed
    Score: 0.022
  10. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacol Bull. 2009; 42(3):5-20.
    View in: PubMed
    Score: 0.020
  11. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007 Dec 15; 62(12):1371-9.
    View in: PubMed
    Score: 0.018
  12. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007 Aug; 68(8):1246-56.
    View in: PubMed
    Score: 0.018
  13. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007 Jul; 68(7):1014-23.
    View in: PubMed
    Score: 0.018
  14. Preventing recurrent depression: long-term treatment for major depressive disorder. J Clin Psychiatry. 2007 Mar; 68(3):e06.
    View in: PubMed
    Score: 0.017
  15. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003 Jul; 160(7):1263-71.
    View in: PubMed
    Score: 0.013
  16. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 1998 Sep; 155(9):1247-53.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.